Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2
Portfolio Pulse from
Valneva SE and LimmaTech Biologics AG have announced the first vaccination in a Phase 2b study of their tetravalent Shigella vaccine candidate, S4V2. Valneva holds an exclusive worldwide license for this vaccine.
November 13, 2024 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Valneva SE has initiated a Phase 2b study for its Shigella vaccine candidate, S4V2, marking a significant step in its development pipeline. This could enhance Valneva's position in the vaccine market.
The initiation of a Phase 2b study is a critical milestone in vaccine development, indicating progress and potential future revenue streams. Valneva's exclusive license for S4V2 could strengthen its market position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90